KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Income from Non-Controlling Interests (2016 - 2019)

CRISPR Therapeutics AG's Income from Non-Controlling Interests history spans 5 years, with the latest figure at $14.2 million for Q1 2019.

  • For Q1 2019, Income from Non-Controlling Interests rose 13.6% year-over-year to $14.2 million; the TTM value through Mar 2019 reached $54.2 million, up 1648.57%, while the annual FY2018 figure was $52.5 million, 45.03% up from the prior year.
  • Income from Non-Controlling Interests for Q1 2019 was $14.2 million at CRISPR Therapeutics AG, up from $13.9 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $14.2 million in Q1 2019 and bottomed at -$35.2 million in Q4 2017.
  • The 5-year median for Income from Non-Controlling Interests is $7.2 million (2017), against an average of $4.0 million.
  • The largest YoY upside for Income from Non-Controlling Interests was 183433.33% in 2017 against a maximum downside of 3519900.0% in 2017.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at -$16000.0 in 2015, then surged by 93.75% to -$1000.0 in 2016, then plummeted by 3519900.0% to -$35.2 million in 2017, then surged by 139.49% to $13.9 million in 2018, then increased by 2.16% to $14.2 million in 2019.
  • Per Business Quant, the three most recent readings for CRSP's Income from Non-Controlling Interests are $14.2 million (Q1 2019), $13.9 million (Q4 2018), and $12.6 million (Q3 2018).